Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (DAAO Inhibitor), as an Add-on Treatment for Schizophrenia in Adults

NCT02261519 is registered in ClinicalTrials.gov with SyneuRx International (Taiwan) Corp as lead sponsor.

NCT NCT02261519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02261519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (DAAO Inhibitor), as an Add-on Treatment for Schizophrenia in Adults
Lead sponsor
SyneuRx International (Taiwan) Corp
Phase
Phase 2/3
Overall status
Terminated
Start date
March 29, 2017
Completion date
November 29, 2023
Enrollment
280 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia